Thymopentin as add-on treatment for severe atopic dermatitis
Randomized study in people · 1994
- What was studied
- 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
- Main finding
- The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.
Reported findings and study design
Findings described in words
Randomized double-blind placebo-controlled add-on trial with serial clinical assessments.
Population or model 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
Dose, route and schedule
Thymopentin 50 mg subcutaneously three times a week for 12 weeks or matching placebo. Both groups could use topical corticosteroids and oral antihistamines.
Protocol source ↗ · Original indexed abstract and publisher record, including the earlier presentation note.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical improvement in severe eczema | Significantly greater with thymopentin plus usual care than with placebo plus usual care | Week 12 |
| Reported drug-related adverse effects | None reported in the abstract. |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The abstract gives no arm-level score changes or group sizes. The 1992 and 1993 conference presentations cited by the paper are earlier presentations of this work.
Source details
Original indexed abstract and publisher record, including the earlier presentation note.
Sources checked
Citation
M. J. Stiller, J. L. Shupack, C. Kenny, L. Jondreau, D. E. Cohen, N. A. Soter. Thymopentin as add-on treatment for severe atopic dermatitis Journal of the American Academy of Dermatology. 1994;30(4):597–602.
Study source ↗ · DOI 10.1016/S0190-9622(94)70068-0 · Bibliography entry · Link to this summary